---
title: "Apogee Therapeutic | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285930474.md"
datetime: "2026-05-11T11:12:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285930474.md)
  - [en](https://longbridge.com/en/news/285930474.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285930474.md)
---

# Apogee Therapeutic | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EBIT: As of FY2026 Q1, the actual value is USD -91.51 M.

#### Financial Summary

-   **Cash Position**: Apogee Therapeutics, Inc. reported cash, cash equivalents, marketable securities, and long-term marketable securities totaling $1.3 billion as of March 31, 2026, an increase from $902.9 million as of December 31, 2025.
-   **Research and Development (R&D) Expenses**: R&D expenses increased to $60.8 million for the quarter ended March 31, 2026, compared to $46.4 million for the same period in 2025. This rise was primarily due to the continued development of the zumilokibart (APG777) and APG990/APG279 programs, increased external-discovery related costs, and higher personnel and equity-based compensation expenses.
-   **General and Administrative (G&A) Expenses**: G&A expenses were $22.0 million for the quarter ended March 31, 2026, up from $16.7 million for the quarter ended March 31, 2025. The increase was mainly attributed to increased personnel-related expenses and equity-based compensation due to increased headcount and the fair value of equity awards.
-   **Net Loss**: Apogee Therapeutics, Inc. reported a net loss of - $74.1 million for the quarter ended March 31, 2026, an increase from a net loss of - $55.3 million for the quarter ended March 31, 2025. This increase was primarily a result of higher R&D and G&A expenses.
-   **Public Equity Offering**: Following the Phase 2 APEX Part A readout in March 2026, Apogee Therapeutics, Inc. completed an upsized public equity offering, generating aggregate gross proceeds of approximately $403 million before deducting underwriting discounts, commissions, and other offering expenses.

#### Operational Metrics - Pipeline Progress

-   **Zumilokibart (APG777) in Atopic Dermatitis (AD)**: APEX Phase 2 Part A 52-week data demonstrated durable maintenance and improved efficacy with every 3- and 6-month dosing in moderate-to-severe AD. At Week 52, 75% of patients with every 3-month dosing and 85% with every 6-month dosing maintained EASI-75 response, while 86% (3-month) and 78% (6-month) maintained IGA 0/1 response from Week 16. Improvements were also observed across the entire population, with IGA 0/1 reaching 72% (3-month) and 52% (6-month) at Week 52, EASI-90 reaching 75% (3-month) and 48% (6-month), and EASI-100 reaching 41% (3-month) and 19% (6-month). Zumilokibart also showed improvements in lesional skin transcriptome across Type 1, 2, and 3 inflammatory pathways.
-   **Zumilokibart in Asthma**: Apogee Therapeutics, Inc. reported positive interim results from the Phase 1b trial in mild-to-moderate asthma in January 2026.
-   **APG279 (zumilokibart + APG990)**: The Phase 1b head-to-head study versus DUPIXENT in AD is fully enrolled with 86 patients.

#### Outlook / Guidance

Apogee Therapeutics, Inc. anticipates releasing APEX Phase 2 Part B 16-week data in Q2 2026 and initiating Phase 3 trials for zumilokibart in atopic dermatitis and interim 24-week data for APG279 in AD in the second half of 2026. The company also plans to provide further details on asthma and eosinophilic esophagitis trials for zumilokibart and plans for APG273 in respiratory indications later this year. Financially, Apogee Therapeutics, Inc. projects its current cash position will fund operating expenses into 2029, supporting a planned Biologics License Application (BLA) filing for atopic dermatitis.

### Related Stocks

- [APGE.US](https://longbridge.com/en/quote/APGE.US.md)

## Related News & Research

- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [UK Finance Minister Reeves, on energy: We stand ready to act if market conditions worsen later this year](https://longbridge.com/en/news/287212577.md)
- [GDEV announces results for the first quarter of 2026 | GDEV Stock News](https://longbridge.com/en/news/286909689.md)
- [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)